Rituxan Access Solutions: What We Do

We would like to welcome you to the Rituxan^® Access Solutions website. We are committed to connecting your patients to their medicine, regardless of their ability to pay. We can help you resolve benefits and coverage issues, as well as find co-pay assistance for underinsured patients. We also have programs to provide free medicine for your uninsured patients. At Rituxan Access Solutions, we provide you with individualized services to meet your patients' specific needs.

Below are some ways Rituxan Access Solutions can help you and your patients with access and reimbursement.

Coverage and Reimbursement

Each year, we help tens of thousands of patients with coverage and reimbursement issues. We have Specialists available who can help your patients connect to the Rituxan^® (rituximab) they need. We can also help you find the right solutions to the coverage and reimbursement issues you might have:

Conducting a benefits investigation
Coding and billing questions you might have
Assisting with a prior authorization for Rituxan when this is required by a health plan
Helping with the appeals process when coverage is denied

Patient Assistance

We know the impact on your patients with financial concerns can be significant. Rituxan Access Solutions can help. We have several options to help the patient who is uninsured or who has been denied coverage by an insurer. We can also help patients who need help with their co-pays.

For information about our co-pay assistance options, click here
For information about how we can help your uninsured patients, click here

Informational Resources

Rituxan Access Solutions provides several services and important information online to help you and your patients on Rituxan. These include the following:

Process Flow

The flow chart seen here gives you an overview of how Rituxan Access Solutions can work for you.

INDICATIONS

RITUXAN^® (Rituximab) is indicated for the treatment of patients with:

Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy
Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens
Previously untreated CD20-positive CLL in combination with FC chemotherapy
Previously treated CD20-positive CLL in combination with FC chemotherapy

People with serious infections should not receive RITUXAN

IMPORTANT SAFETY INFORMATION
RITUXAN can cause serious side effects that can lead to death, including: infusion reactions, tumor lysis syndrome (TLS; kidney failure due to fast breakdown of cancer cells), severe skin and mouth reactions, and progressive multifocal leukoencephalopathy (PML; a rare, serious brain infection).

RITUXAN has also been associated with serious and life-threatening side effects, including: the return of active hepatitis B virus infection with sudden and serious liver problems including liver failure, and death, other serious infections that can lead to death, heart problems, kidney problems, and stomach and serious bowel problems including blockage and tears in the bowel that can sometimes lead to death.

The most common side effects of RITUXAN seen in patients with non-Hodgkin's lymphoma were infusion reactions, fever, chills, low white blood cells, infections, body aches, and tiredness. The most common side effects of RITUXAN in patients with chronic lymphocytic leukemia were infusion reactions and low white blood cells. Before starting treatment with RITUXAN it is important to talk to your doctor about your medical history.

Tell your doctor about any side effect that bothers you or that does not go away. These are not all of the possible side effects with RITUXAN. For more information, ask your doctor.

Please see full Prescribing Information, including the Medication Guide.

Rituxan^® and its logo are trademarks of Biogen Idec, Inc.
The Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.